The following biotech stocks touched a new 52-week high yesterday.
AVEO Pharmaceuticals Inc. (AVEO) is just one step away from getting a U.S. patent for the use of its lead product Fotivda for the treatment of refractory advanced renal cell carcinoma. Shares touched a 52-week intraday high of $9.62 yesterday.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.